The schizophrenia segment emerged dominant in the antipsychotic drugs market in 2018. The segment had acquired an astonishing 45.2% of the antipsychotic drugs market share in the same year owing to the rising prevalence of the disorder. This information is published in a report by Fortune Business Insights, titled, “Antipsychotic Drugs: Global Market Analysis, Insights and Forecast, 2019-2026.” According to the report, the global market was worth US$ 14,963.5 Mn in 2018. However, Fortune Business Insights predicts that the global market will reach US$ 20,539.5 Mn by 2026, exhibiting a CAGR of 4.0% in the forecast period.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antipsychotic-drugs-market-101390
The report on antipsychotic drugs market provides insights into growth opportunities for investors and businesses alike and growth drivers and trends in the market. It offers quantitative and qualitative information on the drivers and growth rate of the segments in the market. The report also comprises of extensive primary and secondary research which aid in providing clients with a clear picture of the anticipated market size and current market scenario.
Leading Players operating in the Antipsychotic Drugs Market are:
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- AstraZeneca
- ALLERGAN
- Vanda Pharmaceuticals Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Alkermes plc
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Other Prominent Players
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/antipsychotic-drugs-market-101390
Indivior, Otsuka, Allergan and Other Market Players Receive Fast Track Approvals
Fortune Business Insights has listed a few key developments that have occurred in the antipsychotic drugs market since the past few years:
- Indivior PLC, a specialty pharmaceuticals business based in the U.K., declared in July 2018 that it received FDA approval for Perseris, a long-acting injectable (LAI) containing risperidone. It is used to treat schizophrenia in adults. Perseris uses the extended-release delivery system that provides a certain level of risperidone which sustains over a month. According to the company, the FDA approval will support adult patients and their healthcare providers by providing a technologically advanced treatment option.
- Allergan, a pharmaceutical company based in Ireland, declared that the FDA approved Vraylar in May 2019. As per the approval, Vraylar can now be used in the treatment of depressive episodes that are associated with bipolar depression (bipolar I disorder) in adult patients. In the U.S., Vraylar can also be used to treat manic episodes occurring due to bipolar I disorder.
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Overview of Prevalence of Psychiatric Disorders by Key Regions
- Pipeline Analysis
- Key Industry Developments
- New Product Launches
- Analysis of the Cost and Burden of Mental Health Disorders
- Analysis of Antipsychotics in Treatment of Dementia
- Analysis of First Generation Antipsychotics versus Second & Third Generation Antipsychotics
- Overview of R&D Initiatives
- Global Antipsychotic Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Disease
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
- Market Analysis, Insights and Forecast – By Therapeutic Class
- First Generation
- Second Generation
- Third Generation
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis – By Disease
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
- Market Analysis – By Therapeutic Class
- First Generation
- Second Generation
- Third Generation
- Market Analysis – By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Analysis – By Country
- U.S.
- Canada
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/antipsychotic-drugs-market-101390
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
